Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 12/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | NPC1 | O15118 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.73 |
| ▸ | MEN1 | O00255 | 8/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977180 | 1.00 | NRP1 (1.00) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16782299 | 0.86 | MAPT (1.00) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13684426 | 0.85 | NRP1 (1.00) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29698045 | 0.85 | NRP1 (1.00) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13684567 | 0.83 | NRP1 (0.71) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23443490 | 0.82 | NRP1 (0.70) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13684526 | 0.80 | NRP1 (0.90) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13679622 | 0.77 | NRP1 (0.83) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL14615300 | 0.77 | MAPT (0.71) | NRP1MAPTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13679550 | 0.76 | MAPT (0.70) | NRP1MAPTCYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2706993-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | Tragex Pharma (FR) | 2014-03-19 | — | — | EP | claimed |
| US-20130041005-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2013-02-14 | — | — | US | claimed |
| WO-2012156289-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2012-11-22 | — | — | WO | claimed |
| EP-2522341-A1 | Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers | Tragex Pharma (FR) | 2012-11-14 | — | — | EP | claimed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | UNIVERSITÉ PARIS CITÉ (FR) | 2022-09-29 | — | — | US | disclosed |
| WO-2021105368-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-06-03 | — | — | WO | disclosed |
| WO-2020245210-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020245210-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-12-10 | — | — | WO | disclosed |
| EP-2706993-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | Tragex Pharma (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-20130041005-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130041005-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2013-02-14 | — | — | US | disclosed |
| US-20130041005-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2013-02-14 | — | — | US | disclosed |
| WO-2012156289-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012156289-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | TRAGEX PHARMA (FR) | 2012-11-22 | — | — | WO | disclosed |
| EP-2522341-A1 | Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers | Tragex Pharma (FR) | 2012-11-14 | — | — | EP | disclosed |
| EP-2522341-A1 | Pharmaceutical compositions comprising Neuropilin inhibitors, and their use for the prevention and/or treatment of angiogenic disorders and cancers | Tragex Pharma (FR) | 2012-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000832-A1 | USE OF NEUROPILIN ANTAGONISTS FOR THE TREATMENT OF ENDOMETRIOSIS | NRP1, PGR, TNFRSF1A | NRP1 1/4885MAPT 4470/4885CYP3A4 2362/4885 |
| US-20220307021-A1 | A NEUROPILIN ANTAGONIST IN COMBINATION WITH A P38ALPHA-KINASE INHIBITOR FOR THE TREATMENT OF CANCER | NRP1, MAPK1, MAPKAP1 | NRP1 1/4885MAPT 2086/4885CYP3A4 4146/4885 |
| US-20130041005-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NEUROPILIN INHIBITORS, AND THEIR USE FOR THE PREVENTION AND/OR TREATMENT OF ANGIOGENIC DISORDERS AND CANCERS | KDR, NRP1, FLT1 | NRP1 2/4885MAPT 2010/4885CYP3A4 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.